173 related articles for article (PubMed ID: 33658646)
1. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Shimomura Y; Hara M; Yamamoto H; Uchida N; Kawakita T; Ashida T; Takada S; Ikeda T; Morishige S; Maruyama Y; Wake A; Ichinohe T; Fukuda T; Takanashi M; Atsuta Y; Ishikawa T
Bone Marrow Transplant; 2021 Jul; 56(7):1691-1699. PubMed ID: 33658646
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kimura T; Kanda J; Fukuda T; Atsuta Y; Ishiyama K
Transplant Cell Ther; 2022 Jun; 28(6):323.e1-323.e9. PubMed ID: 35296446
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Kamijo K; Shimomura Y; Shinohara A; Mizuno S; Kanaya M; Usui Y; Kim SW; Ara T; Mizuno I; Kuriyama T; Nakazawa H; Matsuoka KI; Kusumoto S; Maseki N; Yamaguchi M; Ashida T; Onizuka M; Fukuda T; Atsuta Y; Kondo E
Ann Hematol; 2023 Mar; 102(3):651-661. PubMed ID: 36631705
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kanda J; Fukuda T; Atsuta Y; Aoki J
Bone Marrow Transplant; 2021 Dec; 56(12):3008-3015. PubMed ID: 34489555
[TBL] [Abstract][Full Text] [Related]
5. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
Ueda T; Maeda T; Kusakabe S; Fujita J; Fukushima K; Yokota T; Shibayama H; Tomiyama Y; Kanakura Y
Int J Hematol; 2019 Feb; 109(2):197-205. PubMed ID: 30448938
[TBL] [Abstract][Full Text] [Related]
6. Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.
Mizuno S; Takami A; Kawamura K; Shimomura Y; Arai Y; Konuma T; Ozawa Y; Sawa M; Ota S; Takahashi S; Anzai N; Hiramoto N; Onizuka M; Nakamae H; Tanaka M; Murata M; Kimura T; Kanda J; Fukuda T; Atsuta Y; Yanada M
Transplant Cell Ther; 2022 Nov; 28(11):775.e1-775.e9. PubMed ID: 35921987
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.
DiMaggio E; Zhou JM; Caddell R; Tombleson R; Perkins J; Anasetti C; Khimani F; Pidala J; Nishihori T; Perez L; Betts B; Fernandez HF; Mishra A
Leuk Lymphoma; 2020 Jul; 61(7):1678-1687. PubMed ID: 32133897
[TBL] [Abstract][Full Text] [Related]
8. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Yamashita T; Takami A; Uchida N; Fukuda T; Eto T; Shiratori S; Ota S; Akasaka T; Miyakoshi S; Kondo T; Hidaka M; Kanda J; Atsuta Y; Yano S
Bone Marrow Transplant; 2020 Oct; 55(10):1955-1965. PubMed ID: 32203256
[TBL] [Abstract][Full Text] [Related]
10. Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.
Ueda T; Jo T; Okada K; Arai Y; Sato T; Maeda T; Onishi T; Ueda Y
Int J Hematol; 2020 Feb; 111(2):247-255. PubMed ID: 31701479
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
[TBL] [Abstract][Full Text] [Related]
12. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
15. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
Inamoto Y; Kuwatsuka Y; Tsujimura A; Tokunaga M; Oba T; Miyamura K; Kodera Y
Rinsho Ketsueki; 2006 Jan; 47(1):9-15. PubMed ID: 16479977
[TBL] [Abstract][Full Text] [Related]
17. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
Marsh RA; Hebert K; Kim S; Dvorak CC; Aquino VM; Baker KS; Chellapandian D; Dávila Saldaña B; Duncan CN; Eckrich MJ; Georges GE; Olson TS; Pulsipher MA; Shenoy S; Stenger E; Lugt MV; Yu LC; Gennery AR; Eapen M
J Allergy Clin Immunol; 2022 Mar; 149(3):1097-1104.e2. PubMed ID: 34375618
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity.
Eapen M; Brazauskas R; Hemmer M; Perez WS; Steinert P; Horowitz MM; Deeg HJ
Blood Adv; 2018 Aug; 2(16):2095-2103. PubMed ID: 30135184
[TBL] [Abstract][Full Text] [Related]
19. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Chichra A; Nayak L; Kothari R; Kalantri S; Bonda A; Gokarn A; Punatar S; Mirgh S; Jindal N; Bagal B; Kannan S; Mathew L; Khattry N
Int J Hematol; 2024 Jan; 119(1):71-79. PubMed ID: 37952243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
